Physician profile
Tylan Dudek
NPI 1154176766
$3,303.58
in general payments reported to CMS, 2019-2025
11 companies · $1,586 in 2025
The $1,586 reported for 2025 was more than what 93% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $1,718 · 2025: $1,586.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $2,420 · Food and Beverage: $857 · Education: $27.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $2,419.96 |
| Food and Beverage | $856.62 |
| Education | $27.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,627.28 | 2024 | Interstim, Intellis Adaptivestim |
| Boston Scientific Corporation | $1,302.97 | 2025 | Axonics |
| Coloplast Corp | $116.75 | 2025 | |
| Abbvie INC. | $75.44 | 2024-2025 | |
| Sumitomo Pharma America, INC. | $41.56 | 2024-2025 | Gemtesa |
| Teleflex LLC | $34.05 | 2024-2025 | Quikclot, Solesta |
| Pfizer INC. | $30.00 | 2025 | |
| Astellas Pharma US INC | $22.90 | 2024 | Veozah |
| Esperion Therapeutics, INC. | $18.24 | 2025 | Nexletol |
| Agepha Pharma Fz LLC | $17.80 | 2025 | Lodoco |
| Novo Nordisk INC | $16.59 | 2025 | Wegovy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tylan Dudek listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.